Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics

Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.

Since the introduction of biologics for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and psoriasis (Pso) an increased risk of tuberculosis (TB) reactivation in patients with latent tuberculosis infection (LTBI) has been recorded for anti-TNF agents, while a low or absent risk is associated with the non-anti-TNF targeted biologics. To reduce...

Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.

INTRODUCTION Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and etanercept. Apart from their well-documented therapeutic value, it is still uncertain to what extent they are associated with an increased risk of infectious adverse events. Areas covered: We conducted a systematic review ...

Non-Hodgkin Lymphoma in Psoriatic Arthritis Treated with Sequential, Multiple Anti-TNF-α Agents: A Case Report

The introduction of drugs designed to inhibit the effects of TNF-α significantly modified the prognosis of multiple chronic inflammatory disorders, including rheumatoid arthritis (RA), psoriatic arthritis (PA), psoriasis and ankylosing spondylitis (AS). In these diseases that require long-term treatment with immunosuppressive therapies, there has always been concern that such treatments could i...

DMARD in rheumatoid a rthritis and psoriatic arthrits. The proportions of patients who have re - ceived anti-TNF drugs in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile arthritis

Golimumab : a new anti - TNF agent on the horizon for infl ammatory arthritis

Rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis are highly prevalent infl ammatory arthritides. Various conventional therapies are currently in use, and biologic therapies have also been introduced into the treatment armamentarium. Despite the remarkable effi cacy of the anti-tumor necrosis factor (TNF) agents, there still remains an unmet need for newer anti-TNF agen...